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PC is the most common cancer in men in Europe 
that was ranked third after lung and colorectal cancers 
in 2006 [1]. In Ukraine in 2007 the annual age-stan-
dardized incidence rate of PC was 19.3/100.000 ranking 
fourth after lung, skin and stomach cancers [2].
The PC morbidity growth changed during the last 
20 years from 12.0 in 1989 year to 28.1 in 2007. This 
fact allows to assume the role of the negative impact 
of ecological environmental factors, including the 
consequences of the Chernobyl accident [3]. 
Precancerous changes of prostate gland can be 
also present in young men, are more natural for men 
aged 50 years, though the PC manifestations usually 
diagnosed in patients aged 60–70 years [4]. In 2001, for 
men aged 60 years the PC risk was 30%, the possibility 
of symptomatic manifestations was only 8–9% with PC 
lethal outcome of 2.9% [4–6]. It is well-known that PC 
could be defined by means of autopsy in 30–40% of 
men aged 50–70 years. At the same time, only in 10% 
of cases cancer has clinical manifestations, and in 4% 
the disease leads to lethal outcome [7].
To optimize the early PC detection and for progno-
sis of the disease outcome the complex study should 
be conducted. It should cover the individual histologi-
cal and immunohistochemical tumor characteristics, 
which influence its growth, level of differentiation and 
metastatic activity.
Molecular biology studies elucidated some mecha-
nisms of control of cell division, cell death, signal 
transduction from the receptors to the nucleus. It is 
well-known that р53 gene mutations can promote 
the development of genetic instability. The р53 gene 
functional disorders are general molecular features of 
many human neoplasms. These disorders can occur in 
the normal cells, thus, increasing the possibility of neo-
plastic clone formation, or they take place in malignant 
cells, which promote tumor progression [8, 9]. 
It is also well-known that protein encoded by Всl-2 
pro-oncogene can arrest the apoptosis of prostate 
cells induced by р53 protein or other stimuli, inclu ding 
cytostatic drugs. In case of Bcl-2 protein overexpression 
it acts as oncogene and participates in the formation of 
androgen-resistant phenotype and tumor resistance to 
chemotherapeutic compounds [10, 11]. 
The regulation of cell proliferation is controlled 
by gradual activation of cyclins and corresponding 
cyclin-dependant kinases. The cyclin kinases activity is 
determined by the expression level of relevant cyclins 
and the activity of specific inhibitors. There are several 
families of cyclin kinases inhibitors’ genes. One of the 
most studied is р16INK4a gene, which suppresses the 
activity of cyclin-dependent D kinases, and by this 
obstructs advancing of the cell cycle G1 phase. The 
р16INK4a gene functional disorder or its inactivation can 
lead to the loss of control on cell mitosis [12].
Кі-67 protein is a cell proliferation marker that 
belongs to the regulatory proteins. It assists during 
the cell mitosis and disappears when the cell passes 
to the resting phase or at the time of DNA repair [13]. 
Antibodies against Кі-67 proteins are often used for 
evaluation of proliferating activity of cancer cells, 
including PC cells. Кі-67 index is an independent and 
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widely spread marker for prognosis of PC recurrence 
and patients’ survival [12]. 
Therefore, genes and their products related to 
the tumor progression are considered to be tumor 
mar kers. They are widely used for early diagnostics 
(screening), latent metastasis or disease recurrences 
detection, and also for chemotherapy efficiency moni-
toring and estimation of metastatic tumour potential.
The aim of our study was to evaluate the characte-
ristics of PC morphogenesis, taking into consideration 
the role of proliferation and apoptosis in tumor cells.
MATERIALS AND METHODS
The biopsy specimens were received from PC 
patients, who underwent observation in Institute of 
Urology of Ukrainian Academy of Medical Sciences for 
the period of 2004–2006. All studies were performed 
according to the Institute’s Ethical Committee regu-
lations. The patients’ age was from 58 to 82 years, 
an average age was 70 ± 2.02. All of them are Kiev 
citizens, where density of polluted soil by radioactive 
(Cs137, Cs134) comprises 0.5–5 Curie\1 km2. 
Biopsy specimens were immediately preserved 
in buffered formalin (phosphate buffer, рН 7.4) with 
subsequent preparation of paraffin blocks. Besides 
the ordinary histological examination, the expression 
of tumor suppressor proteins р53 and р16INK4a, apop-
tosis inhibitor Bcl-2, marker of proliferating cells Ki-67 
was examined by immunihistochemistry in 4 microns 
paraffin embedded sections. Immunohistochemical 
staining was conducted by conventional method using 
avidin-biotin-peroxidase complex (ABC) and mouse 
monoclonal antibodies against р53 (DO-7 clone), 
anti-р16INK4a, anti-Bcl-2 and Ki-67 mAbs (DAKO, 
Denmark). Histological verification of tumor was con-
ducted in accordance with the latest WHO International 
classification (2004), defining the total gradation of PC 
according to the Gleason scale. 
To evaluate the level of tissue immunoreactivity the 
semi-quantitative method with estimation of colored cells 
percent among 1000 cells in each specimen was applied. 
Not stained cells has got “0”; < 10% corresponded to “1”; 
more than 10% but < 50% — “2”; > 50% — “3” .
All analyzed tumors were divided into three groups 
in accordance to Gleason scale gradation of PC. The 
first group interconnected 13 tumors with the Gleason 
scale: group 1 (n = 13) — < 5; group 2 (n = 8) — more 
than 5 but less than 8 by the Gleason scale; group 3 
(n = 6) — the highest Gleason scale > 8.
The statistical analysis of the research results was 
carried out by 2 Pearson criteria. The discrepancy 
between the data was considered to be statistically 
relevant with accuracy not less than 95% (р < 0.05).
RESULTS AND DISCUSSION
Upon histological examination of prostate biopsy 
specimens from group 1, the 46% of cases (6 out of 
13) were predominantly small acinic cell PC, which 
developed on the chronic prostatitis background 
with proliferative inflammatory atrophy (РІА) foci, fre-
quently in the combination with РІN zones, which are 
consi dered as precancerous conditions in prostate 
canceroge nesis (Fig. 1, a, b). Moreover, the nuclear 
expression of р53 and Кі-67 proteins and especially 
high cytoplasmic expression of Bcl-2 (> 50% of colo-
red cells) was found in PIA focuses of small (less than 
10% of cells) and expanded (> 10% but < 50%) groups 
of frequently hyperchromic epithelial cells, laying at-
rophied ectatic glands. (Fig. 1, c, d). The expression 
of р16INK4a protein was rather low or absent.
The precancerous foci (PIN and PIA) were found in 
2 out of 8 cases (25%) in group 2, which consisted of 
large and small acinic cell prostate adenocarcinoma 
with generation of cribriform, rarely solid structures. In 
neoplasms of this group the expression level of р53, 
р16INK4a, Bcl-2 proteins and especially of Кі-67 protein 
significantly increased (р < 0.05), in comparison with 
tumors of group 1 (Fig. 2, а, b). 
The third group of PC with predominantly solid 
structures or scirrhus, and Gleason rate higher than 
8 (n = 6) was characterized by the highest nuclear 
expression р53, р16INK4a and Кi-67 (р < 0.05), and also 
by cytoplasmic hyperexpression of Bcl-2 protein. It 
indicated the highest level of proliferative activity of 
cancer cells as a result of Bcl-2 gene alteration and 
overexpression of nuclear Кі-67 (Fig. 2, c, d). 
Our data confirm the existing opinion on histoge-
netic interaction between PIN and adenocarcinoma, 
because they accurately manifest phenotypic simila-
rity. Furthermore, in fact, the occurrence of PIA in PC 
indicates the increased aggressiveness and disposi-
tion to the invasive tumor growth [14].
In accordance to the foregoing information, Ki-67 
index is considered to be the independent prognostic 
marker for PC patients [10]. There also exists the direct 
correlative dependence between the number of Ki-67 
positive tumor cells, and the stage of PC [13]. There is 
the direct dependence between the Кі-67 proliferative 
index, gradation by Gleason scale, tumor infiltration of 
seminal vesicle, tumor size, the existence of PIN locus 
and the level of generic PSА in blood serum [10].
CONCLUSION
Obtained results showed the direct correlation 
between Gleason scale of PC and the expression level 
of р53, р16INK4a, Bcl-2 proteins and, particularly, Кі-67 
marker of proliferating cells. This is evidently empha-
sizing the fact that Gleason scale has both diagnostic 
and prognostic values.
 According to the results of our research, chronic 
prostatitis, which goes with PIN and PIA locus, is 
proved to be favorable background for PC develop-
ment. Moreover, the high expression level of protein 
Bcl-2 reveals itself in PIN and in a lesser degree PIA 
zones, so that it indicates the earlier Bcl-2 gene al-
teration, inhibiting apoptosis. This phenomenon can 
be distinguished as one of the primary and incipient 
presentation of apoptosis molecular affects in PC 
pathogenesis. It can be used as immunohistochemical 
test in order to determine the early preclinical stages 
of PC under biopsy specimen analysis. 
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